Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | TAF1 | P21675 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | GPR3 | P46089 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30644862 | 1.00 | BRD4 (0.34) | BRD4TAF1BRPF1CREBBPCECR2 | |
| SCHEMBL5372057 | 0.79 | MEN1 (0.47) | POLBMEN1MAPK1KMT2A | |
| SCHEMBL7930189 | 0.78 | HTR1A (0.36) | BRD4TAF1BRPF1CREBBPCECR2 | |
| SCHEMBL18299637 | 0.77 | PDE2A (0.32) | BRD4TAF1BRPF1CREBBPCECR2 | |
| SCHEMBL18299986 | 0.75 | KIF11 (0.38) | BRD4TAF1BRPF1CREBBPCECR2 | |
| SCHEMBL18298885 | 0.73 | KIF11 (0.41) | POLBGPR3FFAR4ABL1BCR | |
| SCHEMBL30039737 | 0.73 | KIF11 (0.41) | POLBGPR3FFAR4ABL1BCR | |
| SCHEMBL4484912 | 0.72 | AHR (0.47) | BRD4TAF1BRPF1CREBBPCECR2 | |
| SCHEMBL18300000 | 0.71 | MTNR1A (0.35) | PDE10AGPR3FFAR4KDM4EPTGS1 | |
| Pivalate SCHEMBL30711319 | 0.71 | KMT2A (0.38) | POLBKDM4EPTGS1MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230127-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-12172959-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240182414-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11827602-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827602-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| EP-3896072-B1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-3896072-B1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-3896072-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-107820494-A | Nuclear receptor modulators | 艾伯维公司 | 2018-03-20 | — | — | CN | disclosed |
| WO-2017167950-A1 | SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2017046258-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046255-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2016200851-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016200851-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2016180696-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | BRD4 758/4885TAF1 897/4885BRPF1 1191/4885 |
| US-20250230127-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | IDO1, IDO2, IRF3 | BRD4 358/4885TAF1 4100/4885BRPF1 2721/4885 |
| US-11827602-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | IDO1, IDO2, IRF3 | BRD4 346/4885TAF1 4064/4885BRPF1 2616/4885 |
| US-20240182414-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | IDO1, IDO2, IRF3 | BRD4 346/4885TAF1 4064/4885BRPF1 2616/4885 |
| US-12172959-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | IDO1, IDO2, IRF3 | BRD4 346/4885TAF1 4064/4885BRPF1 2616/4885 |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | BRD4 758/4885TAF1 897/4885BRPF1 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.